NUTRIBAND INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 4.47 USD | -5.30% |
|
+33.04% | +92.67% |
| 05-16 | Nutriband Inc. Appoints Sergei Glinka to Its Board of Directors | CI |
| 05-01 | Tranche Update on Nutriband Inc.'s Equity Buyback Plan announced on December 30, 2021. | CI |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration
Nutriband Inc. is engaged in the development of a portfolio of transdermal pharmaceutical products. Its development pipeline consists of transdermal products that are based on proprietary AVERSA abuse-deterrent transdermal technology. Its lead product under development is AVERSA Fentanyl, an abuse deterrent fentanyl transdermal system that combines an approved generic fentanyl patch with its AVERSA abuse deterrent transdermal technology to reduce the abuse and misuse of fentanyl patches. Its development pipeline also includes AVERSA Buprenorphine and AVERSA Methylphenidate. It is developing a portfolio of transdermal pharmaceutical products to deliver already approved drugs or biologics that are typically delivered by injection but with the potential to improve compliance and therapeutic outcomes through transdermal delivery. AVERSA technology can be incorporated into any transdermal patch to prevent the abuse, misuse, diversion, and accidental exposure of drugs with abuse potential.
Calendar
27/05/2024
- Q1 2025 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| +92.67% | 48.99M | |
| -5.43% | 181B | |
| +4.30% | 114B | |
| -3.09% | 68.29B | |
| +5.86% | 52.24B | |
| +8.15% | 44.3B | |
| +7.52% | 42.73B | |
| +25.54% | 32.52B | |
| +17.85% | 26.02B | |
| +1.00% | 25.91B |
- Stock Market
- Equities
- NTRB Stock
- News Nutriband Inc.
- Nutriband Signs Supplier Deal With KT Tape
